Active Ingredient History

  • Now
Ixazomib (MLN2238) is an active metabolite of orally bioavailable proteasome inhibitor ixazomib citrate (MLN9708), which hydrolyzes upon administration. Ixazomib citrate was approved under the name Ninlaro for the treatment of multiple myeloma in patients who have received at least one prior therapy. In vitro studies has shown that ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$2506.5700 - $3088.6133
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ixazomib | ixazomib citrate | mln2238 | mln9708 | mln 9708 | mln-9708 | ninlaro


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue